Literature DB >> 30598390

Neurocognitive functioning in adults with phenylketonuria: Report of a 10-year follow-up.

R Feldmann1, J Osterloh2, S Onon2, J Fromm3, F Rutsch2, J Weglage2.   

Abstract

BACKGROUND: The long-term prognosis of early treated phenylketonuria (PKU) is still under discussion. Aim of this controlled long-term study was to assess the neurological and neuropsychological outcome in adult patients with early-treated PKU.
METHODS: We investigated 35 patients with early-treated classical PKU aged 29 to 51 years (mean age 41 years) and 18 healthy controls matched for age and socioeconomic status. Patients and controls were assessed for their intelligence quotient (IQ), attention and information-processing abilities. Magnetic resonance imaging (MRI) of the brain was performed in all patients. Neuropsychological assessments and MRI were repeated at a five-year and a ten-year follow-up.
RESULTS: In the entire interval IQ, information processing and attention of patients and controls remained constant. At both follow-up assessment times the IQ scores were significantly lower in patients compared to controls. Older adult patients (> 42 years) showed poorer information processing and attention at both assessment times compared to young adult patients (< 42 years) and controls. IQ, information processing and attention showed no correlation to imaging results. IQ, however, was significantly correlated to blood phenylalanine (Phe) levels in patients´ childhood and adolescence, and Phe levels had been higher in the adolescent years of older adult patients.
CONCLUSIONS: Cognitive performance in adult patients with early-treated PKU does not seem to deteriorate in a ten-year interval. Neuropsychological assessment in adults with PKU revealed neurocognitive impairment particularly in older adult patients. This seems to refer to an early relaxation of diet that was recommended when the older patients were adolescents. Results indicate a benefit of dietary control during adolescence in PKU.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30598390     DOI: 10.1016/j.ymgme.2018.12.011

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  4 in total

1.  Unmet needs in PKU and the disease impact on the day-to-day lives in Brazil: Results from a survey with 228 patients and their caregivers.

Authors:  Ana Maria Martins; Andre Luiz Santos Pessoa; Andrea Amaro Quesada; Erlane Marques Ribeiro
Journal:  Mol Genet Metab Rep       Date:  2020-07-22

Review 2.  Phenylketonuria.

Authors:  Francjan J van Spronsen; Nenad Blau; Cary Harding; Alberto Burlina; Nicola Longo; Annet M Bosch
Journal:  Nat Rev Dis Primers       Date:  2021-05-20       Impact factor: 52.329

3.  AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria.

Authors:  Daelyn Y Richards; Shelley R Winn; Sandra Dudley; Sean Nygaard; Taylor L Mighell; Markus Grompe; Cary O Harding
Journal:  Mol Ther Methods Clin Dev       Date:  2019-12-24       Impact factor: 6.698

4.  Cognitive Outcomes and Relationships with Phenylalanine in Phenylketonuria: A Comparison between Italian and English Adult Samples.

Authors:  Cristina Romani; Filippo Manti; Francesca Nardecchia; Federica Valentini; Nicoletta Fallarino; Claudia Carducci; Sabrina De Leo; Anita MacDonald; Liana Palermo; Vincenzo Leuzzi
Journal:  Nutrients       Date:  2020-10-03       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.